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ABSTRACT 
Objective: The process of angiogenesis is finely balanced by Proangiogenic factors and antiangiogenic factors. Any imbalance between these factors 
may result in a group of diseases with varied morphologic and pathologic changes, called angiogenesis dependent diseases. One has to arrest the 
growth of unwanted blood vessels like in metastasis of tumour, arthritis, retinopathies, etc. As the angiogenesis is simultaneously controlled by 
several factors, one needs to target the whole process through a holistic approach i.e. targeting more than one mechanism at a time. Objective of our 
study was to evaluate antiangiogenic potentials of Camellia sinensis and Boswellia serrata in whole animal models along with their safety 
individually as well as in combination.  
Methods: These extracts were evaluated for their antiangiogenic effect using three models – Chicken Chorioallentoic membrane assay, Rat 
Subcutaneous air sac and Mesenteric window angiogenesis.  
Results: The results of toxicity study showed that aqueous extracts of Camellia sinensis and Boswellia serrata are safe on oral administration in 
acute as well as repeated dose toxicity studies. It also showed antiangiogenic effects of individual extracts as well as their combinations. The study 
suggests that there may be synergistic effect in these extracts particularly in mesenteric window model.  
Conclusion: From the study it can be concluded that these extracts can be clinically evaluated on angiogenesis dependent diseases.  
Keywords: Boswellia serrata, Camellia sinensis, Safety, Angiogenesis, CAM, Angiogenesis dependent disease, Arthritis, Metastasis. 
 
INTRODUCTION 
Angiogenesis is the process of formation of new blood vessels from 
pre-existing microvasculature. It is a fundamental process in 
formation of new blood vessels. It is essential in reproduction, 
development and wound repair. In these conditions, angiogenesis 
turns on for a short period and then it is completely inhibited [1, 2]. 
Under physiological conditions angiogenesis is highly regulated 
phenomenon, because of several pro-angiogenic and anti-angiogenic 
factors in body [3]. In development of fetus, process of angiogenesis is a 
very powerful process and plays a very important role. Disruption of this 
process leads to abortions and / or teratogenicity [4].  
Angiogenesis is a complex process involving various mechanical and 
chemical triggers [5]. Such triggers can be grouped as pro-
angiogenic and anti-angiogenic factors. In body more than 20 
different pro-angiogenic and anti-angiogenic factors finely control 
the physiologic angiogenesis [1, 2, 3, 6]. In the pathologic process of 
angiogenesis, the balance between these pro and anti-angiogenic 
factors gets disturbed resulting a variety of disorders, which can be 
grouped as angiogenesis dependent diseases.  
They involve – arthritis, ischaemias, metastasis of tumour etc. In 
addition, numerous inflammatory, allergic, infectious, traumatic, 
metabolic or hormonal disorders, which are characterized by 
excessive vessel growth, including atherosclerosis, restenosis, 
transplant arteriopathy, warts, allergic dermatitis, scar keloids, 
peritoneal adhesions, synovitis, osteomyelitis, asthma, nasal polyps, 
choroideal and intraocular disorders, retinopathy of prematurity, 
diabetic retinopathy, leukomalcia, AIDS, endometriosis, uterine 
bleeding, ovarian cysts etc. Angiogenesis also plays a role in obesity.  
Applications of angiogenesis research can be categorised in 
following areas… 
1. Diagnostic Applications – diagnosis of angiogenesis dependent 
diseases.  
2. Acceleration of angiogenesis in wound healing and ischaemias or 
infarctions in several tissues.  
3. Inhibition of angiogenesis in neoplasia, arthritis, retinopathies 
due to corneal vascularisation and such other angiogenesis 
dependent diseases.  
Researchers are heading towards development of newer deliveries 
using monoclonal antibody techniques targeting various steps in 
tumour metastasis and also have come out with some monoclonal 
antibody based agents in clinical practice. Examples of such drugs 
include ‘Bevacizumab acting on VEGF-A, Sunitinib and vatalanib – 
tyrosine kinase inhibitors, Sorafenib – acting on Raf Kinase etc. [8, 9, 
10] while several others under different phases of clinical or 
preclinical trials [11]. On the other hand researchers are trying to 
target tumour through different delivery systems [12, 13, 14].  
Even though having so many advantages antiangiogenic and 
anticancer drugs, based on targeting single receptor or signaling 
systems have some limitations in their use. Some clinical 
experiences have found toxicities for these agents. Basically 
angiogenesis related signaling pathways have an important role in 
haematopoiesis, myelopoiesis, and endothelial cell survival. 
Toxicities indicate that angiogenesis involves several other 
processes in body viz. immune system, blood flow regulation and 
coagulation cascade. Though anti-angiogenic agents are developed 
to inhibit / affect one pathway, its deleterious effects may be 
observed on other homeostatic mechanisms [2].  
Natural health products can inhibit angiogenesis along with having 
other anticancer mechanisms. These products have been shown to 
act on various molecular pathways other than angiogenesis, 
including epidermal growth factor receptor, the HER2/nu gene, 
COX-2 enzymes, NF κ-β transcription factor, the protein kinases, etc. 
Several herbs are traditionally being used in the treatment of cancer 
– some explored some still to be discovered. Explored herbs for 
anticancer activity still need further polishing so as to isolate the 
exact component / group of components responsible for its 
anticancer activity [15, 16]. Several Indian as well as Chinese 
medicinal herbs have been shown to be effective in curing ischemic 
diseases, arthritis, retinal angiopathies as well as other angiogenesis 
dependent diseases, but their functions were not scientifically 
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tested. This work describes antiangiogenic properties of Boswellia 
Serrata (BA) extract in in vivo animal models. 
MATERIALS AND METHODS  
Chemicals, reagents, and animals 
Mast cell secretagogue Compound 48/80 was purchased from Sigma 
Life Sciences, Bangalore, India, Brown Leghorn Chicken eggs were 
purchased from Simran Hatcheries, Dhule, Boswellia serrata extract 
was purchased from Natural Remedies, Bangalore, while Camellia 
sinensis leaves were purchased from local market and got 
authenticated by Department of Botany, P. R. Ghogare College of 
Science, Dhule. All other chemicals used for the study were of 
analytical grade, purchased from Qualigens, Mumbai, India.  
Animals were procured from animal house of SPTM. The protocols 
for animal studies were approved by IAEC, of the School of 
Pharmacy and Technology Management, Shirpur. Standard diet for 
animals was purchased from Amrut Agrovet, Sangli. 
Extraction of Camellia sinensis 
Dried leaves of Camellia sinensis were extracted by hot maceration 
method [17] with little modification. In brief, weighed quantity of CS 
leaves macerated in 1:40 proportion in water at 800C for 2 hours. 
Resultant solution was filtered through muslin cloth and filtrate was 
dried at 600
Phytochemical investigations 
C to constant weight. The extract thus obtained was 
stored in refrigerator till further use. The extract was termed as (GT) 
Both extracts were subjected for qualitative phytochemical 
investigation and extraction specific parameters, like ash value, acid 
insoluble ash, and Loss on drying.  
Standardization of Camellia sinensis extract 
a. Total phenolics in the Camellia sinensis extract were calculated 
using Folin - Ciocalteu Assay [18]. Extract (1 mL) was added to a 
flask containing distilled water (9 mL). Then Folin-Ciocalteu’s 
phenol reagent (1 mL) was added and the mixture was mixed 
thoroughly. After 5 min, 7% sodium carbonate (10 mL) was added. 
The mixture was diluted to 25 mL with the addition of distilled 
water (4 mL) and allowed to stand at room temperature for 90 min. 
Absorbance was measured at 760 nm using a Perkin Elmer lambda 
510 spectrophotometer.  
Total Phenolics are expressed as mg Gallic acid equivalents (GAE)/g 
samples. The same procedure was repeated to all standard Gallic 
acid solutions (0–1000 mg, 0.1 ml-1) and standard curve was 
obtained. 
b. Total flavonoid content was determined using Aluminium 
Chloride colourimetric assay [18]. Extract (1 mL) was added to 
distilled water (4 mL) in a flask. Then, 5% NaNO2 (0.3 mL) was 
added. After 5 min, 10% AlCl3 (0.3 mL) was added and after 6 min, 1 
M NaOH (2 mL) was added. The mixture was diluted to 10 mL with 
distilled water. The absorbance of the solution was measured at 510 
nm using a Perkin Elmer lambda 510 spectrophotometer. The 
results are expressed as mg catechin equivalents (CE)/g samples. 
Standardization of Boswellia serrata extract (BA) 
Standardization of Boswellia serrata extract was done using HPLC 
method of estimation of boswellic acids. Briefly a sample of 
Boswellia serrata extract was prepared by dissolving 40mg 
Boswellia serrata extract in 10 ml solvent system being used. The 
resultant was filtered through disc filter to result a clear solution. 
This was further diluted to result 250mcg/ml solution. The marker 
for Boswellia serrata extract (a combination of boswellic acid and 
alpha keto boswellic acid) was used as standard. The standard stock 
solution of 2mg/ml was prepared. It was further diluted to result 20
Chromatographic conditions: -  
 
stock of 100mcg/ml. A serial dilutions of it were then prepared and 
the Chromatogram of the standard was recorded.  
System - Perkin- Elmer Series 200 HPLC unit with Kromacil C18 
column and lambda 25 spectrophotometric detector.  
Solvent system: - Acetonitrile: Water (90:10) at pH 4.0 adjusted with 
Glacial acetic acid.  
Detector: - Spectrophotometric detector at 260nm wavelength.  
Runtime allowed was 08 minute.  
Acute Toxicity Studies of Extracts 
Acute toxicity studies were carried out following OECD 423 
guidelines [19]. Following toxic class method, both extracts were 
evaluated to 2000 mg/Kg dose. No any signs of toxicity were 
observed even at this dose. So the extracts were classed as 
unclassified. Therefore in further studies dose of 250 mg/Kg and 
125 mg/Kg are used.  
Repeated Dose Toxicity studies of extracts 
Repeated dose toxicity of both the extracts was carried out at 
250mg/Kg, 500mg/Kg and 1000 mg/Kg dose to evaluate any 
adverse effect of chronic use following OECD 408 guidelines [20]. 
Adult Wistar albino rats weighing between 170 to 200g were 
selected as test animals. 5 male and 5 female rats were used for each 
group. Animals were treated for 90 days with a daily dosing and 
observed for biological, hematologic, and behavioral parameters as 
per OECD guidelines. 
In Vivo models of Angiogenesis 
Chicken Chorioallentoic Membrane Assay 
Chorioallantoic membrane (CAM) assay was performed following 
method described by Nguyen and his colleagues, with little 
modification [21]. Fertile Brown Leghorn chicken eggs were 
obtained from a local hatchery. 70% ethanol was sprayed on these 
eggs for disinfecting their surface. They were kept in humidified 
incubator at 37.50C (±1.50C). Eggs were rotated 4 to 6 times a day to 
ensure uniform vssel development. On embryonic day 4 a window 
was cut on the shell over the embryo to expose chorioallentoic 
membrane (CAM). Eggs were sealed again with cellophane film and 
incubated for further two days. On the 6th embryonic day 10 
microliter of either 0.9% sodium chloride (Normal saline) solution 
or solutions of extracts (10mg/ml) were placed on intact CAM. 
These eggs were again incubated for further 24 hours. After this 
period, i.e. on 7th
For statistics one way ANOVA followed by Dunnett’s multiple 
comparison tests was followed. 
 embryonic day the eggs were observed for number 
of primary, secondary and tertiary vessels formed, nature of blood 
vessels and area of the CAM covered. 
Rat Subcutaneous Air Sac Angiogenesis 
Angiogenesis was induced in rat in the subcutaneous space to result 
an inflated Air Sac following method described by Lichtenberg J, 
with little modification [22].To adult Wistar albino rats about 10 ml 
of air was administered subcutaneously on the back, on alternate 
day in order to maintain the sac inflated. Gradually the sac became 
thick. The animals were divided in seven groups of six each. The 
animals were treated with twice a day oral administration of the 
aqueous suspensions of extracts for 12 days at 125 mg/Kg and 250 
mg/Kg. The clipped skin was dissected to expose the formed 
membrane on which blood vessels grow. The area was analyzed for 
No. of blood vessels formed and area covered by newly formed 
blood vessels. 
For statistics one way ANOVA followed by Dunnett’s multiple 
comparison test was followed. 
Rat Mesenteric Window Angiogenesis 
Mesenteric window angiogenesis was performed as described by 
Norrby [23]. Wistar Albino rats were separated in 7 groups of 6 
animals each and treated similarly except the drugs. Rats were 
administered intraperitoneally 9 doses at 12 hours interval (4.5 
days) Mast cell secretagogue compound in 2mg/kg bodyweight, 
suspended in 0.9% normal saline solution. Animals were treated 
with oral administration of extracts for 14 days at 125 mg/Kg or 250 
mg/Kg twice daily 1 hour before administration of Mast Cell 
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Secretagogue compound. Extracts were suspended in 1% 
Carboxymethyl Cellulose solution. After 14 days the animals were 
sacrificed and mesentery was removed carefully to view four 
windows per animal. Isolated mesenteries were washed carefully, 
stained with hematoxylene, and eosin. The area in each window was 
analyzed for No. of blood vessels formed and area covered by newly 
formed blood vessels. 
For statistics one way ANOVA followed by Dunnett’s multiple 
comparison test was followed. 
RESULTS 
1. Extraction specific parameters 
The extraction yield for Camellia sinensis extract was found to be 
35%W/W. Moisture content in the dried extract was calculated to be 
4.04% W/W, total ash was found to be 1.7%, while acid insoluble 
ash was 0.3%. For Boswellia serrata extract moisture content was 
found to be 0.59%W/W, Total ash was 1.8%W/W, while acid 
insoluble ash was found to be 0.2%. 
 
2. Phytochemical investigation 
 
Table 1: Preliminary Phytochemical investigation of extracts 
Test Camellia sinensis Extract  Boswellia serrata Extract 
Tests for alkaloid 
Wagner’s test - - 
Test for carbohydrate 
Molish Test - + 
Test for glycosides 
Borntrager’s test (Anthraquinone) - - 
Killer Kiliani test (Cardiac glycosides) - - 
Froth test (Saponin glycosides) - - 
Test for flavonoids 
Shinoda test + + 
Test for tannins 
Ferric Chloride test + - 
Test for proteins 
Biuret test - - 
Hydrolysis test - - 
Test for steroids / terpinoids 
Salkowaski test - - 
(+ indicates the presence of phytochemical while – indicates absence.) 
 
3. Standardisation of Camellia sinensis extract 
Total phenolics in the Camellia sinensis extract were calculated using 
Folin - Ciocalteu Assay. Phenolic content in the extract was 
calculated on the basis of Gallic acid equivalent per unit dry weight 
of sample. It was found that sample extract of Camellia sinensis 
contain 82.03 mg Gallic acid equivalents /g of dry extract. Fig. 1 
represents the calibration curve and the line equation for estimation 
of total phenolics.  
 
 
Fig. 1: graph of total phenolic content of Camellia sinensis 
extract 
 
Total flavonoid content was determined using Aluminium Chloride 
colourimetric assay. It was found to contain 20.24 mg catechin 
equivalent /g of dry extract.  
 
 
Fig. 2: graph of total flavonoid content of Camellia sinensis 
extract. 
 
4. Standardisation of Boswellia serrata extract 
Boswellia serrata extract was standardised for presence of Boswellic 
acid and alpha keto boswellic acid.  
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Fig. 3: HPLC chromatogram of Boswellic acid marker (A) versus 
extract of Boswellia serrata (B) 
5. Acute Toxicity studies:  
The acute toxicity studies were carried out using OECD guidelines 
following toxic class method. As there were no observable adverse 
effects even at 2000mg/Kg, extracts were characterised as 
“unclassified” as per OECD. Therefore doses selected were 
250mg/kg and 125mg/kg.  
6. Repeated dose toxicity studies:  
Repeated dose toxicity was carried out following OECD guidelines 
408. As per the observations and also from histopathologic studies, 
it was observed that even at the doses of 1000mg/Kg, these extracts 
were safe and showed no significant change in physiologic, 
biochemical or biological parameters, when administered alone.  
The combination of 500 mg/kg of both the extracts also did not 
show any toxicity in these animals indicating safety in combination. 
7. Effect of extracts on Chicken Chorioallentoic membrane 
angiogenesis (CAM):  
Chorioallentoic membrane represents hypoxic model of 
angiogenesis. The developing embryo undergoes hypoxia to develop 
new blood vessels, which partly mimics angiogenesis in tumors. 
Administration of GT extract in the dose of 10mg/ml reduces 
angiogenic response to such hypoxia to about 43%, while BA was 
able to reduce it to 34%.  
In combination whereas ½ of each extract was able to reduce the 
angiogenesis to 43% but in 1:1 proportion such reduction is about 
54%. 
 
Table 2: Effects of crude drug extracts on primary, secondary and tertiary blood vessels in CAM. (n=20) 
Group Treatment Group Primary Blood vessels Secondary Blood Vessels Tertiary Blood Vessels Percent inhibition 
in tertiary blood 
vessels 










































Values are expressed as mean ±SEM comparisons were made between control and test groups. Statistical significance expressed as: **p<0.01. 
 
8. Effect of extracts on Dorsal air sac angiogenesis in rats 
When air is administered in subcutaneous area of rat, it results in 
inflammation of the region and formation of synovium like 
membrane. Angiogenesis in such membrane was found to be 
reduced when the animals were treated with CS extracts.  
As presented in Table 3, even though GT extract at 125 mg/Kg is not 
able to reduce the rate and extent of angiogenesis significantly, there 
is significant reduction (49.39%) by 250mg/Kg dose of GT extract. 
Boswellia serrata extract at 250mg/kg dose is found to be significant 
in reducing formation of such blood vessels. BA was able to reduce 
the rate and extent of vascularisation in RAS by about 27%, while 
combination of 125mg/Kg each of these extracts is insignificant. But 
if combined in 250mg/Kg each, the angiogenesis in RAS can be 
reduced to about 50%. It indicates combination does not prove 
efficient than GT alone in RAS. 
  
Table 3: Effect of crude drug extracts on formation of blood vessels in subcutaneous air sac in rats. (n=06) 
Group Treatment No. of Blood Vessels Formed 
1 Control 14.83 ±0.48 
2 GT 125 13.00 ±0.37 
3 GT 250 7.33 ±0.49** 
4 BA 125 13.33 ±0.42 
5 BA 250 10.83 ±0.87** 
6 GT + BA 125 10.17 ±0.48** 
7 GT + BA 250 7.17 ±0.60** 
Values are expressed as mean ±SEM comparisons were made between control and test groups. Statistical significance expressed as: **p<0.01 
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9. Effect of extracts on mesenteric window angiogenesis 
Mesenteric window angiogenesis is the model of angiogenesis 
representing role of inflammatory mediators in angiogenesis. New 
blood vessels are developed in rat mesentery because of mast cell 
secretagauge compound 48/80. According to our studies, Boswellia 
serrata extract is able to reduce such kind of angiogenesis 
significantly. As shown in table 4, extract is able to reduce the rate of 
new blood vessel formation in inflammation mediated angiogenesis 
to about 60 %. When animals treated with GT extract with control 
animals, it was found that GT extracts have an ability to reduce rate 
of formation of new blood vessels in mesentery. CS extract was 
found to show significant reduction (27.72%) in formation of blood 
vessels in mesenteric windows at dose of 250 mg/kg. Combination 
of these two extracts in 250mg/Kg each produces significant 
antiangiogenic response by causing 70%reduction in formation of 
new blood vessels. 
 
Table 4: Effect of crude drug extracts on formation of blood 
vessels in mesenteric windows in rats. (4 windows per animal, 
n=6) 
Group Treatment No. of Blood Vessels Formed 
1 Control 15.79 ±0.15 
2 BA 125 12.92±0.75** 
3 BA 250 6.25±0.66** 
4 GT 125 13.67±0.42 
5 GT 250 11.5±0.47** 
6 GT + BA 125 8.88±0.68** 
7 GT + BA 250 4.67±0.55** 
Values are expressed as mean ±SEM comparisons were made 




Angiogenesis – one of the key players in angiogenesis dependent 
disorders is the process involving interplay of various endogenous 
and exogenous factors. There is an established link between 
angiogenesis, tissue hypoxia inflammation, oxidation of cellular 
components and variety of other tissue messengers and circulating 
mediators. Findings of this research work suggest that targeting one 
or two factors or receptors appear to be insufficient. Instead a 
system based approach is expected to fight such disorders.  Both 
natural products, camellia as well as Boswellia are well tolerated by 
animals even in as high as 1000 mg/Kg dose, administered 
repeatedly. Antioxidant potential of Camellia sinensis might help 
reducing the angiogenesis in Choriolallentoic membrane model by 
about 43%, while by up to 50% in Subcutaneous air sac model. On 
the other hand Boswellia serrata extract is able to reduce the rate 
and extent of angiogenesis in mesenteric window model, which may 
be because of its anti-inflammatory potential. Combination of these 
extracts, even though fail to establish a clear cut additive effect in 
CAM or RSA, but the same can be seen in MWA model.  These results 
suggest Camellia sinensis and Boswellia serrata have promising 
future in the treatment of such angiogenesis dependent disorders. 
These extracts can be used alone or in combination. Further 
evaluation of these extracts is needed in human being and in 
particular models of specific angiogenesis dependent disorders. 
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